Phase 3RecruitingAge-related condition

A Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection

A Multicenter Phase III Clinical Study Evaluating the Diagnostic Performance and Safety of PET for the Deposition of Aβ Plaques in the Brain of Participants With Normal Cognitive Function, MCI and AD Using [18F]Fluorbetazine Injection

Sponsor
HTA Co., Ltd. (Industry)
Enrollment
400 planned
Conditions
Mild Cognitive Impairment (MCI); Alzheimer's Disease (AD)
Interventions
[18F]Fluorbetazine injection
Ages
adults, older adults
Registry
NCT07764679

Full record on ClinicalTrials.gov

From the registry

A multicenter phase III clinical study evaluating the diagnostic performance and safety of PET for the deposition of Aβ plaques in the brain of participants with normal cognitive function, MCI and AD using \[18F\]Fluorbetazine injection.

Primary outcomes

  • The sensitivity and specificity of PET imaging visual interpretation results compared to true standards after a single intravenous injection of [18F]Fluorbetazine injection in participants with AD induced MCI, AD dementia and normal cognitive.

History

  1. Study completion expected

  2. Primary completion expected

  3. Registered

  4. Started